propranolol has been researched along with Malignant Melanoma in 18 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 9.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 7.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "Propranolol is a vasoactive drug that shows antiangiogenic and antitumour activities in melanoma." | 7.85 | Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. ( Bearzi, C; Buoncervello, M; Catalano, L; Gabriele, L; Giordani, L; Maccari, S; Macchia, D; Marano, G; Rampin, A; Rizzi, R; Spada, M; Stati, T, 2017) |
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 5.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| " Using pharmacological approaches, evaluation of Ki-67 expression by flow cytometry and luciferase-based cAMP assay, we found that treatment with isoproterenol, a β-AR agonist, increased cAMP levels in B16F10 melanoma cells without affecting cell proliferation." | 4.12 | Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation. ( Ambrosio, C; Ascione, B; Grò, MC; Maccari, S; Marano, G; Matarrese, P; Molinari, P; Stati, T; Vezzi, V; Vona, R, 2022) |
| " Here, we investigated the effects of SNS signaling in murine monocyte-derived macrophages (moMФ) and dendritic cells (DCs) and further combined the nonspecific β-blocker propranolol with a peptide cancer vaccine for the treatment of melanoma in mice." | 4.02 | The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells. ( Chen, SH; Chen, Z; Hinkle, L; Liu, Y; Mai, J; Meng, C; Pan, PY; Shen, H; Xu, Y; Zhang, L, 2021) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 3.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "Propranolol is a vasoactive drug that shows antiangiogenic and antitumour activities in melanoma." | 3.85 | Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. ( Bearzi, C; Buoncervello, M; Catalano, L; Gabriele, L; Giordani, L; Maccari, S; Macchia, D; Marano, G; Rampin, A; Rizzi, R; Spada, M; Stati, T, 2017) |
| "A 45-year-old woman with marital and working troubles, a personal history positive for malignant melanoma, and a family history of vitiligo presented with adrenergic urticaria (AU), which at first responded to propranolol, but later became unresponsive to both ?-blockers and antihistamines." | 3.78 | Adrenergic urticaria and rheumatoid arthritis in a patient with melanoma: an intricate medical management. ( Capella, GL, 2012) |
| "Different pharmacologic drugs (isadrin, obsidan, phentolamine) changing adrenergic processes are shown to have different effect on the growth and development of lung metastases." | 3.67 | [Changes in the metastasis of experimental tumors and in the antimetastatic effect of cytostatics in their pharmacological action on adrenergic processes]. ( Balitskiĭ, KP; Riabukha, VN; Smelkova, MI; Veksler, IG, 1984) |
| "Congenital or atypical nevi of the child benefit from genetic progress or improvement of clinical knowledge." | 2.49 | [What’s new in pediatric dermatology?]. ( Lacour, JP, 2013) |
| "Propranolol was tested on four UM and two CM cell lines to determine the effects of this beta-blocker." | 1.51 | Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma. ( Burnier, JV; Burnier, MN; Bustamante, P; de Alba Graue, PG; Dias, AB; Goyeneche, A; Jin, E; Miyamoto, D; Tsering, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Q | 1 |
| Long, J | 1 |
| Hu, L | 1 |
| Chen, Z | 2 |
| Li, Q | 1 |
| Hu, G | 1 |
| Maccari, S | 3 |
| Buoncervello, M | 2 |
| Ascione, B | 2 |
| Stati, T | 3 |
| Macchia, D | 2 |
| Fidanza, S | 1 |
| Catalano, L | 2 |
| Matarrese, P | 2 |
| Gabriele, L | 2 |
| Marano, G | 3 |
| Hinkle, L | 1 |
| Liu, Y | 1 |
| Meng, C | 1 |
| Mai, J | 1 |
| Zhang, L | 2 |
| Xu, Y | 1 |
| Pan, PY | 1 |
| Chen, SH | 1 |
| Shen, H | 1 |
| Vona, R | 1 |
| Vezzi, V | 1 |
| Grò, MC | 1 |
| Ambrosio, C | 1 |
| Molinari, P | 1 |
| Bustamante, P | 1 |
| Miyamoto, D | 1 |
| Goyeneche, A | 1 |
| de Alba Graue, PG | 1 |
| Jin, E | 1 |
| Tsering, T | 1 |
| Dias, AB | 1 |
| Burnier, MN | 1 |
| Burnier, JV | 1 |
| Gandhi, S | 1 |
| Pandey, MR | 1 |
| Attwood, K | 1 |
| Ji, W | 1 |
| Witkiewicz, AK | 1 |
| Knudsen, ES | 1 |
| Allen, C | 1 |
| Tario, JD | 1 |
| Wallace, PK | 1 |
| Cedeno, CD | 1 |
| Levis, M | 1 |
| Stack, S | 1 |
| Funchain, P | 1 |
| Drabick, JJ | 1 |
| Bucsek, MJ | 1 |
| Puzanov, I | 1 |
| Mohammadpour, H | 1 |
| Repasky, EA | 1 |
| Ernstoff, MS | 1 |
| De Giorgi, V | 3 |
| Grazzini, M | 2 |
| Benemei, S | 3 |
| Marchionni, N | 2 |
| Botteri, E | 1 |
| Pennacchioli, E | 1 |
| Geppetti, P | 3 |
| Gandini, S | 2 |
| Patanè, S | 1 |
| Kao, J | 1 |
| Luu, B | 1 |
| Lacour, JP | 1 |
| Wrobel, LJ | 1 |
| Le Gal, FA | 1 |
| Zhou, C | 1 |
| Chen, X | 1 |
| Zeng, W | 1 |
| Peng, C | 1 |
| Huang, G | 1 |
| Li, X | 1 |
| Ouyang, Z | 1 |
| Luo, Y | 1 |
| Xu, X | 1 |
| Xu, B | 1 |
| Wang, W | 1 |
| He, R | 1 |
| Zhang, X | 1 |
| Liu, J | 1 |
| Knepper, TC | 1 |
| He, Y | 1 |
| McLeod, HL | 1 |
| Rampin, A | 1 |
| Spada, M | 1 |
| Giordani, L | 1 |
| Bearzi, C | 1 |
| Rizzi, R | 1 |
| Fraser, K | 1 |
| Capella, GL | 1 |
| Veksler, IG | 1 |
| Riabukha, VN | 1 |
| Smelkova, MI | 1 |
| Balitskiĭ, KP | 1 |
2 reviews available for propranolol and Malignant Melanoma
| Article | Year |
|---|---|
Can propranolol prevent progression of melanoma?
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Melanoma; Neoplasm Recurrence, Local; Prop | 2019 |
[What’s new in pediatric dermatology?].
Topics: Adolescent; Child; Dermatitis, Atopic; Dermatology; Hemangioma, Capillary; Humans; Melanoma; Neoplas | 2013 |
1 trial available for propranolol and Malignant Melanoma
| Article | Year |
|---|---|
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
15 other studies available for propranolol and Malignant Melanoma
| Article | Year |
|---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
α-Adrenoceptor stimulation attenuates melanoma growth in mice.
Topics: Animals; Catecholamines; Epinephrine; Ligands; Melanoma; Mice; Mice, Knockout; Propranolol; Receptor | 2022 |
The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Dendritic Cells; Melanoma; Mice; Monocytes; No | 2021 |
Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation.
Topics: Adrenergic beta-Agonists; Cell Line, Tumor; Cell Proliferation; Humans; Isoproterenol; Melanoma; Pro | 2022 |
Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Sc | 2019 |
Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
Topics: Aged; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Mi | 2018 |
Improving the Propranolol Treatment of Melanoma-Reply.
Topics: Cell Proliferation; Cohort Studies; Humans; Melanoma; Off-Label Use; Propranolol | 2018 |
Improving the Propranolol Treatment of Melanoma.
Topics: Cell Proliferation; Cohort Studies; Humans; Melanoma; Off-Label Use; Propranolol | 2018 |
Inhibition of human melanoma growth by a non-cardioselective β-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; | 2015 |
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; G1 | 2016 |
Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Resp | 2017 |
67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
Topics: Acne Vulgaris; Dermatology; Hemangioma; Humans; Keratosis, Actinic; Melanoma; Methicillin-Resistant | 2009 |
[β-blockers: a new and emerging treatment for melanoma].
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Evidenc | 2012 |
Adrenergic urticaria and rheumatoid arthritis in a patient with melanoma: an intricate medical management.
Topics: Adrenergic beta-Antagonists; Arthritis, Rheumatoid; Female; Glucocorticoids; Histamine Antagonists; | 2012 |
[Changes in the metastasis of experimental tumors and in the antimetastatic effect of cytostatics in their pharmacological action on adrenergic processes].
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation, Preclinical; Drug Therapy, Combin | 1984 |